One of us recently received exciting molecular testing results: a patient’s newly diagnosed metastatic colorectal cancer expressed microsatellite instability, a predictive biomarker for immunotherapy. The patient fell into the minority of patients with metastatic colorectal cancer for whom precision oncology truly alters the natural history of disease, potentially prolonging survival by years. Providing biomarker-driven immunotherapy certainly exemplified the tenets of precision oncology.